Trial · NCT07913620
"Experimental Study on Stroke Rehabilitation Based on Dual-Task Exercises"
NCT07913620, Not applicable, Recruiting, Matia Foundation
3 sourcestrials-2026-11-12-0.4.0
Download JSON
Cite this record
ConductScience Library. "Experimental Study on Stroke Rehabilitation Based on Dual-Task Exercises". Trials, record NCT07913620. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913620
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- "Experimental Study on Stroke Rehabilitation Based on Dual-Task Exercises"
- NCT number
- NCT07913620
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 80 participants, estimated
- Lead sponsor
- Matia Foundation
- Conditions
- Stroke
- Interventions
- Dual-Task Perturbation & Computerized Cognitive Training, Single-Task Perturbation-Based Balance Training
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Berg Balance Scale, BBS | Baseline, 12 weeks into intervention, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | Statistically significant improvements in functional balance recovery are expected in favor of the intervention group compared to the control group. Furthermore, a higher proportion of subjects in the experimental group is expected to achieve the Minimal Clinically Important Difference (MCID)-defined as an increase of ≥6 points on the Berg Balance Scale (BBS)-and to demonstrate a favorable transition toward lower fall-risk categories (BBS scores \>41 points). |
| Secondary | Short-Term and Working Memory | Baseline, end of rehabilitation at 16 weeks, and 6-month follow-up post-intervention. | * Evaluation Tool: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV), Digit Span Subtest. * Variable Type: Quantitative continuous / Primary secondary outcome. * Domain \& Construct Assessed: Auditory short-term memory, focused attention, verbal working memory, and executive control in post-stroke individuals. * Measurement Sub-domains \& Metrics: 1. Digit Span Forward: Measures immediate auditory retention and short-term memory capacity. Metrics recorded include total raw score (correct trials) and memory span (maximum sequence length accurately repeated in direct order). 2. Digit Span Backward: Measures working memory capacity, mental manipulation, and executive control. Metrics recorded include total raw score (correct trials) and memory span (maximum sequence length accurately repeated in reverse order). 3. Total Digit Span Raw Score: Cumulative composite raw score combining correct trials from both Forward and Backward modalities. |
| Other | Time Up and Go (TUG) | Baseline, 12 weeks into intervention, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | Outcome Measure Title: Functional Mobility, Frailty, and Overall Health Status. Variable Type: Quantitative continuous Domain Assessed: Dynamic balance, functional mobility, gait speed, overall health deterioration, and frailty status in post-stroke individuals. Operational Metric: Time recorded in seconds (s) required for the participant to stand up from a standard armchair, walk 3 meters at a comfortable and safe pace, turn around, walk back to the chair, and sit down again. |
| Other | 10-Meter Walk Test (10MWT) | Baseline, 12 weeks into intervention, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | The 10-Meter Walk Test (10MWT) assesses walking speed in meters per second (m/s) over a short distance. Participants are instructed to walk along a 10-meter pathway at their \[comfortable / maximum\] self-selected pace. Acceleration and deceleration distances of 2 meters each are provided at the start and end of the course; only the central 6 meters are timed using a digital stopwatch. The primary outcome metric is the mean walking speed (m/s) calculated from \[e.g., two / three\] trials. |
| Other | Frailty Phenotype According to Fried Criteria | Baseline, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | Assessment of frailty status using Fried's Frailty Phenotype model, which evaluates five criteria: unintentional weight loss (\>10 lbs or \>5% of body weight in the past year), self-reported exhaustion, low physical activity level, slow gait speed, and weak handgrip strength. Participants are classified based on the number of criteria present: Robust / Non-frail: 0 criteria met Pre-frail: 1 or 2 criteria met Frail: 3 or more criteria met |
| Other | Hamilton Depression Rating Scale (HDRS) | Baseline, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | Assessment of depression severity using the \[17-item / 21-item\] Hamilton Depression Rating Scale (HDRS). The scale evaluates depressive symptoms including mood, feelings of guilt, suicide ideation, insomnia, work and activities, agitation, anxiety, somatic symptoms, and loss of weight. Items are scored on either a 3-point (0 to 2) or 5-point (0 to 4) Likert scale. The total score ranges from 0 to \[52 para 17 items / 66 para 21 items\], with higher scores indicating greater severity of depressive symptoms. Score interpretation (for the 17-item version): 0-7: Normal / Remission 8-13: Mild depression 14-18: Moderate depression 19-22: Severe depression ≥23: Very severe depression |
| Other | Hamilton Anxiety Rating Scale (HAM-A / HARS) | Baseline, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | Assessment of anxiety severity using the 14-item Hamilton Anxiety Rating Scale (HAM-A). The scale evaluates both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a 5-point Likert scale ranging from 0 (not present) to 4 (severe). The total score ranges from 0 to 56, with higher scores indicating greater severity of anxiety symptoms. Score interpretation: \< 17: Mild anxiety severity 17-24: Mild to moderate anxiety severity 25-30: Moderate to severe anxiety severity \> 30: Severe anxiety |
| Other | Ashworth Scale (AS) | Baseline, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | Assessment of muscle spasticity using the Modified Ashworth Scale (MAS). The scale measures resistance encountered during passive muscle stretching in the target muscle groups \[e.g., upper/lower limb flexors or extensors\]. The scale ranges from 0 to 4 across 6 scoring categories: 0: No increase in muscle tone. 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion (ROM). 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM. 2: More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved. 3: Considerable increase in muscle tone, passive movement difficult. 4: Affected part(s) rigid in flexion or extension. Higher scores indicate greater muscle spasticity. |
| Other | Brunnstrom Stages of Motor Recovery | Baseline, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | Assessment of motor recovery following stroke using the Brunnstrom Stages of Motor Recovery for the affected limbs \[e.g., upper extremity, lower extremity, hand\]. The scale evaluates the progression of voluntary movement control from reflex-dominated movement to normal voluntary function. The scale consists of 6 sequential stages (1 to 6): Stage 1: Flaccidity; no voluntary movement in the affected limb. Stage 2: Basic limb synergies appear; spasticity begins to develop. Stage 3: Voluntary control of movement synergies; spasticity reaches its peak. Stage 4: Movement combinations out of synergy begin to develop; spasticity begins to decline. Stage 5: More complex movement combinations learned; basic synergies lose dominance. Stage 6: Spasticity disappears; individual joint movements become possible and coordination approaches normal. Higher stages indicate greater motor recovery and voluntary motor control (range: 1 to 6). |
| Other | Stroke-Specific Quality of Life Scale (ECVI-38) | Baseline, end of rehabilitation at 16 weeks, 6-month and 12 month follow-up post-intervention. | Assessment of health-related quality of life (HRQoL) using the 38-item Stroke-Specific Quality of Life Scale (Escala de Calidad de Vida para el Ictus - ECVI-38). The scale evaluates eight domains: Physical Function, Feelings, Communication, Cognition, Family Relationships, Social Relationships, Socio-Economic Function, and Work/Productivity. Each item is rated on a 5-point Likert scale ranging from 1 to 5. Domain scores and the overall mean score are normalized on a scale from 0 to 100, where higher scores indicate poorer quality of life / greater impairment. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33013625 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Other outcome | ConductCognition |
| Trail Making Test B | Other outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913620
GET https://conductscience.org/api/trials/v1/NCT07913620/registered